# Applicant

Focus Diagnostics, Inc. 10703 Progress Way Cypress, California 90630 USA

Establishment Registration No. 20233

# Contact Person

Constance Bridges tel 714.220.1900 fax 714.995.6921 cbridges@focusdx.com

# Summary Date

May 31, 2007

Proprietary Name Generic Name Classification Predicate Devices

HerpeSelect Express IgG   
Herpes Simplex Virus Types 1 and 2 Serological Assays   
Class II   
HerpeSelect 1 and 2 Immunoblot IgG   
HerpeSelect-2 ELISA IgG

# Reference Method

HerpeSelect 1 and 2 Immunoblot IgG

# Device Description

Rapid Lateral Flow assay for the qualitative detection of human IgG class antibodies to HSV-2

# Intended Use

HeSeprap liv h indicated or testing sexually active adults or pregnant women to aid in the presumptive diagnosis of HSV-2 infection.

The HerpeSelect $^ \mathrm { \textregistered }$ Express IgG device has not been established for use in the pediatrics population, for neonatal screening, or or testing immuocompromised patients.This kit is not intended or sel-testing, and this test is neither FDA cleared nor approved for testing blood or plasma donors.

# Test Principle

HerpeSelect® Express is an immunochromatographic test that uses purified antigen bound to a nitrocellulose man p e p enit he l bu   e e u yol se r uan G depos betwenhe bufer pad and the ampl depson zone t mirat acoss the lulat pur yuan s h slc  rate,he V capues any HSV- ntods presnt n the sampl.  the s o SV- antibody present he sample l pink line in the control zone of the device indicates the device is working correctly.

# EXPECTED VALUES

An outside investigator assesed the device with masked, prospected samples from 1) sexually active adults $( { \mathfrak { n } } =$ 575), and 2) from pregnant women $( \mathbf { n } = 4 0 1$ ). The reference method was the Focus Diagnostics HerpeSelect 1 and 2 Immunoblot IgG.The observed prevalences and the hypothetical predictive values for the two populations are shown below. The positive predictive value wll decrease proportionally to the prevalence of HV infection as reflected in the following table.

510(k) Summary of Safety and Effectiveness   
HerpeSelect 1 and 2 Plexus IgG Catalog No. RT0920G Prepared May 31, 2007 Revised September 21, 2007 Page 2 of 13

<table><tr><td rowspan=2 colspan=1>Observed Prevalence</td><td rowspan=1 colspan=4>Observed Rate of Positives in Indicated Populations</td></tr><tr><td rowspan=1 colspan=1>HerpeSelect ExpressIn Sera</td><td rowspan=1 colspan=1>HerpeSelect ExpressIn Venous Whole Blood</td><td rowspan=1 colspan=1>HerpeSelect ExpressIn Capillary Whole Blood</td><td rowspan=1 colspan=1>HerpeSelectImmunoblot</td></tr><tr><td rowspan=1 colspan=1>HSV-2 positives(+)with Pregnant Women</td><td rowspan=1 colspan=1>(118/400) 29.5%</td><td rowspan=1 colspan=1>(118/400) 29.5%</td><td rowspan=1 colspan=1>(124/400) 31.0%</td><td rowspan=1 colspan=1>(117/399) 29.3%</td></tr><tr><td rowspan=1 colspan=1>HSV-2 positives(+)with Sexually ActiveAdults</td><td rowspan=1 colspan=1>(241/573) 42.1%</td><td rowspan=1 colspan=1>(240/573) 41.9%</td><td rowspan=1 colspan=1>(243/573) 42.4%</td><td rowspan=1 colspan=1>(226/570) 39.6%</td></tr></table>

Prevalence vs. Hypothetical Predictive Values (In Pregnant Women)   

<table><tr><td rowspan=2 colspan=1>Prevalence</td><td rowspan=1 colspan=2>Serum</td><td rowspan=1 colspan=2>Venous Whole Blood</td><td rowspan=1 colspan=2>Capillary Whole Blood</td></tr><tr><td rowspan=1 colspan=1>PPV</td><td rowspan=1 colspan=1>NPV</td><td rowspan=1 colspan=1>PPV</td><td rowspan=1 colspan=1>NPV</td><td rowspan=1 colspan=1>PPV</td><td rowspan=1 colspan=1>NPV</td></tr><tr><td rowspan=1 colspan=1>50%</td><td rowspan=1 colspan=1>96.7%</td><td rowspan=1 colspan=1>94.8%</td><td rowspan=1 colspan=1>97.0%</td><td rowspan=1 colspan=1>93.4%</td><td rowspan=1 colspan=1>95.7%</td><td rowspan=1 colspan=1>94.9%</td></tr><tr><td rowspan=1 colspan=1>40%</td><td rowspan=1 colspan=1>95.2%</td><td rowspan=1 colspan=1>96.5%</td><td rowspan=1 colspan=1>95.6%</td><td rowspan=1 colspan=1>95.5%</td><td rowspan=1 colspan=1>93.7%</td><td rowspan=1 colspan=1>96.6%</td></tr><tr><td rowspan=1 colspan=1>30%</td><td rowspan=1 colspan=1>92.7%</td><td rowspan=1 colspan=1>97.7%</td><td rowspan=1 colspan=1>93.4%</td><td rowspan=1 colspan=1>97.1%</td><td rowspan=1 colspan=1>90.5%</td><td rowspan=1 colspan=1>97.8%</td></tr><tr><td rowspan=1 colspan=1>25%</td><td rowspan=1 colspan=1>90.8%</td><td rowspan=1 colspan=1>98.2%</td><td rowspan=1 colspan=1>91.6%</td><td rowspan=1 colspan=1>97.7%</td><td rowspan=1 colspan=1>88.1%</td><td rowspan=1 colspan=1>98.2%</td></tr><tr><td rowspan=1 colspan=1>20%</td><td rowspan=1 colspan=1>88.1%</td><td rowspan=1 colspan=1>98.7%</td><td rowspan=1 colspan=1>89.1%</td><td rowspan=1 colspan=1>98.3%</td><td rowspan=1 colspan=1>84.7%</td><td rowspan=1 colspan=1>98.7%</td></tr><tr><td rowspan=1 colspan=1>15%</td><td rowspan=1 colspan=1>83.9%</td><td rowspan=1 colspan=1>99.0%</td><td rowspan=1 colspan=1>85.3%</td><td rowspan=1 colspan=1>98.8%</td><td rowspan=1 colspan=1>79.7%</td><td rowspan=1 colspan=1>99.1%</td></tr><tr><td rowspan=1 colspan=1>10%</td><td rowspan=1 colspan=1>76.6%</td><td rowspan=1 colspan=1>99.4%</td><td rowspan=1 colspan=1>78.5%</td><td rowspan=1 colspan=1>99.2%</td><td rowspan=1 colspan=1>71.2%</td><td rowspan=1 colspan=1>99.4%</td></tr><tr><td rowspan=1 colspan=1>5%</td><td rowspan=1 colspan=1>60.8%</td><td rowspan=1 colspan=1>99.7%</td><td rowspan=1 colspan=1>63.3%</td><td rowspan=1 colspan=1>99.6%</td><td rowspan=1 colspan=1>53.9%</td><td rowspan=1 colspan=1>99.7%</td></tr></table>

revalence vs. Hypothetical Predictive Values (In Sexually Active Adults)   

<table><tr><td rowspan=2 colspan=1>Prevalence</td><td rowspan=1 colspan=2>Serum</td><td rowspan=1 colspan=2>Venous Whole Blood</td><td rowspan=1 colspan=2>Capillary Whole Blood</td></tr><tr><td rowspan=1 colspan=1>PPV</td><td rowspan=1 colspan=1>NPV</td><td rowspan=1 colspan=1>PPV</td><td rowspan=1 colspan=1>NPV</td><td rowspan=1 colspan=1>PPV</td><td rowspan=1 colspan=1>NPV</td></tr><tr><td rowspan=1 colspan=1>50%</td><td rowspan=1 colspan=1>92.0%</td><td rowspan=1 colspan=1>93.6%</td><td rowspan=1 colspan=1>92.5%</td><td rowspan=1 colspan=1>93.3%</td><td rowspan=1 colspan=1>92.0%</td><td rowspan=1 colspan=1>93.7%</td></tr><tr><td rowspan=1 colspan=1>40%</td><td rowspan=1 colspan=1>88.4%</td><td rowspan=1 colspan=1>95.7%</td><td rowspan=1 colspan=1>89.1%</td><td rowspan=1 colspan=1>95.4%</td><td rowspan=1 colspan=1>88.5%</td><td rowspan=1 colspan=1>95.7%</td></tr><tr><td rowspan=1 colspan=1>30%</td><td rowspan=1 colspan=1>83.1%</td><td rowspan=1 colspan=1>97.2%</td><td rowspan=1 colspan=1>84.1%</td><td rowspan=1 colspan=1>97.0%</td><td rowspan=1 colspan=1>83.1%</td><td rowspan=1 colspan=1>97.2%</td></tr><tr><td rowspan=1 colspan=1>25%</td><td rowspan=1 colspan=1>79.3%</td><td rowspan=1 colspan=1>97.8%</td><td rowspan=1 colspan=1>80.4%</td><td rowspan=1 colspan=1>97.7%</td><td rowspan=1 colspan=1>79.3%</td><td rowspan=1 colspan=1>97.8%</td></tr><tr><td rowspan=1 colspan=1>20%</td><td rowspan=1 colspan=1>74.2%</td><td rowspan=1 colspan=1>98.3%</td><td rowspan=1 colspan=1>75.5%</td><td rowspan=1 colspan=1>98.2%</td><td rowspan=1 colspan=1>74.2%</td><td rowspan=1 colspan=1>98.3%</td></tr><tr><td rowspan=1 colspan=1>15%</td><td rowspan=1 colspan=1>67.0%</td><td rowspan=1 colspan=1>98.8%</td><td rowspan=1 colspan=1>68.5%</td><td rowspan=1 colspan=1>98.7%</td><td rowspan=1 colspan=1>67.0%</td><td rowspan=1 colspan=1>98.8%</td></tr><tr><td rowspan=1 colspan=1>10%</td><td rowspan=1 colspan=1>56.1%</td><td rowspan=1 colspan=1>99.2%</td><td rowspan=1 colspan=1>57.8%</td><td rowspan=1 colspan=1>99.2%</td><td rowspan=1 colspan=1>56.1%</td><td rowspan=1 colspan=1>99.3%</td></tr><tr><td rowspan=1 colspan=1>5%</td><td rowspan=1 colspan=1>37.7%</td><td rowspan=1 colspan=1>99.6%</td><td rowspan=1 colspan=1>39.3%</td><td rowspan=1 colspan=1>99.6%</td><td rowspan=1 colspan=1>37.7%</td><td rowspan=1 colspan=1>99.6%</td></tr></table>

Note: Sexuallt dult anpreant oe pulatins differet ggraphicareas ma produifent fecy stutins fromh tablebovach aoatoryoul etablis eqeyisrutins specific patient populations.

# PERFORMANCE CHARACTERISTICS Summary of Studies

<table><tr><td rowspan=1 colspan=1>Study</td><td rowspan=1 colspan=1>Criteria</td><td rowspan=1 colspan=1>Specificity andSensitivity withHerpeSelectImmunoblot</td></tr><tr><td rowspan=1 colspan=1>Pregnant Women (Indicated population) in Serum</td><td rowspan=1 colspan=1>SpecificitySensitivity</td><td rowspan=1 colspan=1>92.3% (108/117)96.1% (271/282)</td></tr><tr><td rowspan=1 colspan=1>Pregnant Women (Indicated population) in Venous Whole Blood</td><td rowspan=1 colspan=1>SpecificitySensitivity</td><td rowspan=1 colspan=1>93.2% (109/117)97.2% (274/282)</td></tr><tr><td rowspan=1 colspan=1>Pregnant Women (Indicated population) in Capillary Whole Blood</td><td rowspan=1 colspan=1>SpecificitySensitivity</td><td rowspan=1 colspan=1>94.9% (111/117)95.4% (269/282)</td></tr><tr><td rowspan=1 colspan=1>Sexually Active Adults (Indicated population) in Serum</td><td rowspan=1 colspan=1>SpecificitySensitivity</td><td rowspan=1 colspan=1>92.9% (210/226)91.8% (315/343)</td></tr></table>

# K071510

510(k) Summary of Safety and Effectiveness   
HerpeSelect 1 and 2 Plexus IgG Catalog No. RT0920G Prepared May 31, 2007 Revised September 21, 2007 Page 3 of 13

<table><tr><td rowspan=1 colspan=1>Study</td><td rowspan=1 colspan=1>Criteria</td><td rowspan=1 colspan=1>Specificity andSensitivity withHerpeSelectImmunoblot</td></tr><tr><td rowspan=1 colspan=1>Sexually Active Adults (Indicated population) in Venous WholeBlood</td><td rowspan=1 colspan=1>SpecificitySensitivity</td><td rowspan=1 colspan=1>93.4% (211/226)92.4% (317/343)</td></tr><tr><td rowspan=1 colspan=1>Sexually Active Adults (Indicated population) in Capillary WholeBlood</td><td rowspan=1 colspan=1>SpecificitySensitivity</td><td rowspan=1 colspan=1>93.4% (211/226)92.4% (317/343)</td></tr><tr><td rowspan=1 colspan=1>Non-Sexually Active Adults (Low Prevalence Population) in Serum</td><td rowspan=1 colspan=1>SpecificitySensitivity</td><td rowspan=1 colspan=1>0% (0/2)100% (101/101)</td></tr><tr><td rowspan=1 colspan=1>Non-Sexually Active Adults (Low Prevalence Population) in VenousWhole Blood</td><td rowspan=1 colspan=1>SpecificitySensitivity</td><td rowspan=1 colspan=1>0% (0/2)100% (101/101)</td></tr><tr><td rowspan=1 colspan=1>Non-Sexually Active Adults (Low Prevalence Population) inCapillary Whole Blood</td><td rowspan=1 colspan=1>SpecificitySensitivity</td><td rowspan=1 colspan=1>0% (0/2)100% (101/101)</td></tr><tr><td rowspan=1 colspan=1>CDC HSV/CMV Panel</td><td rowspan=1 colspan=1>SpecificitySensitivity</td><td rowspan=1 colspan=1>100% (35/35)98.5% (64/65)</td></tr><tr><td rowspan=1 colspan=1>Cross-reactivity:</td><td rowspan=1 colspan=1>Overall Cross-reactivity</td><td rowspan=1 colspan=1>4.2% (9/213)</td></tr><tr><td rowspan=1 colspan=1>Inter-Lot Reproducibility</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>&lt;10%</td></tr><tr><td rowspan=1 colspan=1>Inter-Operator &amp; Inter-Site Reproducibility</td><td rowspan=1 colspan=1>% CV range</td><td rowspan=1 colspan=1>≤ 65.0%</td></tr><tr><td rowspan=1 colspan=1>Intra-Operator Reproducibility</td><td rowspan=1 colspan=1>% CV</td><td rowspan=1 colspan=1>≤35.1%</td></tr><tr><td rowspan=1 colspan=1>Intra-Site Reproducibility</td><td rowspan=1 colspan=1>% CV of positives</td><td rowspan=1 colspan=1>≤ 23.0%</td></tr><tr><td rowspan=1 colspan=1>Interference</td><td rowspan=1 colspan=2>No effect on sample results</td></tr></table>

# Sensitivity and Specificity with Pregnant Women $( \boldsymbol { \mathsf { n } } = \mathbf { 4 0 1 } )$

External Investigator I $( \mathtt { n } = 1 6 1$ ), External Investigator II $( { \mathfrak { n } } = 1 2 0 )$ , and External Investigator III $( { \tt n } = 1 2 0 )$ assessed the device's agreement in subjects from pre-natal clinics.The capillary and venous whole blood and sera from al oeiv bj  col  nmaskthe telvgatoTh sxt mdical school clinic in Southeastern United States; External investigator $\mathrm { I I }$ was a pre-natal clinic located n e Milantic Region f the Unite States; and xtealinvtigator  was n - ractice inheMic Regon f the United States. The Focus Diagnostics HerpeSelect  and 2 Immunoblot IgG was the typing reece method for calculation of sensitivity and speciicty.

# Pregnant Women in Sera

The HerpeSelect Express showed $9 6 . 1 \%$ (271/282) agreement with Immunoblot negatives, and $9 2 . 3 \%$ (108/117) agreement with Immunoblot positives. Two samples were not tested in Immunoblot.

O 0  heHerpeSel blot I was gaive wi  osve with 11T s

O te 282 negative HerpeSelect Immunoblot sra, Express was negative with $9 6 . 1 \%$ (271/282), positive with 9, and invalid with 2.

O the 11 positive HerpeSelect Immoblot sra, Express was negative with 6, posiive with $9 2 . 3 \%$ (108/117), and invalid with 3.

# K071510

510(k) Summary of Safety and Effectiveness   
HerpeSelect 1 and 2 Plexus IgG Catalog No. RT0920G Prepared May 31, 2007 Revised September 21, 2007 Page 4 of 13

HerpeSelect Express compared to Immunoblot with Pregnant Women in Sera $\mathbf { ( n = 4 0 1 ) }$   

<table><tr><td rowspan=2 colspan=1>Immunoblot</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=3>Express</td><td rowspan=2 colspan=1>Specificity</td><td rowspan=2 colspan=1>Sensitivity</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Invalid</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>117</td><td rowspan=1 colspan=1>108</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>92.3% (108/117)95%CI 85.9-96.4%</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>282</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>271</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>96.1% (271/282)95%CI 93.1-98.0%</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>N/A</td></tr></table>

Two samples were not tested.

# Pregnant Women in Venous Whole Blood

The HerpeSelect Express showed $9 7 . 2 \%$ (274/282) agreement with Immunoblot negatives, and $9 3 . 2 \%$ (109/117) agreement with Immunoblot positives.

Of the 401 samples, the HerpeSelect Immunoblot IgG was negative with 282 and positive with 117. Two samples we otes;f qny n

Of h 282 negative HerpeSelect Immunoblot samples, Express was negative with $9 7 . 2 \%$ (274/282), positive with 8, ind invalid with 0.

O the 11 positive HerpeSelect Immunoblot samples, Express was negative with 8, positive with $9 3 . 2 \%$ (109/117), and invalid with 0.

HerpeSelect Express compared to Immunoblot with Pregnant Women in Venous Whole Blood $\mathbf { ( n = 4 0 1 ) }$ .   

<table><tr><td rowspan=2 colspan=1>Immunoblot</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=3>Express</td><td rowspan=2 colspan=1>Specificity</td><td rowspan=2 colspan=1>Sensitivity</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Invalid</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>117</td><td rowspan=1 colspan=1>109</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>93.2% (109/117)95%CI 87.0-97.0%</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>282</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>274</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>97.2% (274/282)95%CI 94.5-98.8%</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>N/A</td></tr></table>

Two samples were not tested.

# Pregnant Women in Capillary Whole Blood

The HerpeSelect Express showed $9 5 . 4 \%$ (269/282) agreement with Immunoblot negatives, and $9 4 . 9 \%$ (111/117) agreement with Immunoblot positives.   
Of the 401 samples, the HerpeSelect Immunoblot IgG was negative with 282 and positive with 117. Two samples were not tested in Immunoblot due to insufficient quantities   
Of the 282 negative HerpeSelect Immunoblot samples, Express was negative with $9 5 . 4 \%$ (269/282), positive with 12, and invalid with 1.   
O the 117 positive HerpeSelect Immunoblot samples, Express was negative with 6, positive with $9 4 . 9 \%$ (111/117), and invalid with 0.

HerpeSelect Express compared to Immunoblot with Pregnant Women in Capillary Whole Blood $\mathbf { ( n = 4 0 1 ) }$   

<table><tr><td rowspan=2 colspan=1>Immunoblot</td><td rowspan=2 colspan=1>n&#x27;</td><td rowspan=1 colspan=3>Express</td><td rowspan=2 colspan=1>Specificity</td><td rowspan=2 colspan=1>Sensitivity</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Invalid</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>117</td><td rowspan=1 colspan=1>111</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>94.9% (111/117)95%CI 89.2-98.1%</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>282</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>269</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>95.4% (269/282)95%CI 92.2-97.5%</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>N/A</td></tr></table>

Two samples were not tested.

# HerpeSelect Express Percent Negative and Positive Agreement with HerpeSelect 2 (ELISA) in Pregnant Women $\mathbf { ( n = 4 0 1 ) }$

The gold-standard reference method was the Focus Diagnostics HerpeSelect  and 2 Immunoblot IgGfor calculatin o nsitivity and specificiy.The device was also evaluated with the HerpeSelect ELISA IgG a cleared predicate device which is not required for regulatory clearance for typing assay.

HerpeSelect Express Agreement with ELISA in Sera with Pregnant Women

The HerpeSelect Express showed $9 6 . 7 \%$ (267/276) agreement with ELISA negatives in sera, and $9 1 . 7 \%$ (111/121), agreement with ELISA positives. Two ELISA equivocals were excluded. One sample was not tested due to improper storage.

O 401 sra he HerpeSelec  LIA Igwa egaive with76, pive wit 1, and euiva wit .   
sample was not tested due to improper storage.

Of the 276 negative HerpeSelect 2 ELISA sera, Express was negative with $9 6 . 7 \%$ (267/276), positive with 7, and invalid with 2.

Of the 121 positive HerpeSelect 2 ELISA sera, the Express was negative with 7, positive with $9 1 . 7 \%$ (111/121), and invalid with 3.

Express Agreement with ELISA in Sera with Pregnant Women $( \mathbf { n } = 4 0 1 )$   

<table><tr><td rowspan=2 colspan=1>ELISA</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=3>HerpeSelect Express</td><td rowspan=2 colspan=1>% Agreement</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Invalid</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>121</td><td rowspan=1 colspan=1>111</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>91.7% (111/121)95%CI 85.3-96.0%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>276</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>267</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>96.7% (267/276)95%CI 93.9-98.5%</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>N/A</td></tr></table>

' One sample was not tested in ELISA.

HerpeSelect Express Agreement with ELISA in Venous Whole Blood with Pregnant Women

The HerpeSelect Express showed $9 7 . 8 \%$ (271/277) agreement with ELISA negatives in samples, and $9 2 . 6 \%$ (112/121) agreement with ELISA positives.Two ELISA equivocals were excluded and one sample was not tested due to improper storage.

Of the 401 samples, the HerpeSelect 2 ELISA $\mathrm { I g G }$ was negative with 277, positive with 121, and equivocal with 3.   
One sample was not tested due to improper storage.

Of the 277 negative HerpeSelect 2 ELISA samples, Express was negative with $9 7 . 8 \%$ (271/277), positive with 6, and invalid with 0.

O ivHSec  s   iv  v $9 2 . 6 \%$ (112/121), and invalid with 0.

Express Agreement with ELISA in Venous Whole Blood with Pregnant Women $\mathbf { \Omega } ( \mathbf { n } = 4 0 1 \dot { \mathbf { \Omega } }$   

<table><tr><td rowspan=2 colspan=1>ELISA</td><td rowspan=2 colspan=1>n{$</td><td rowspan=1 colspan=3>HerpeSelect Express</td><td rowspan=2 colspan=1>% Agreement</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Invalid</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>121</td><td rowspan=1 colspan=1>112</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>92.6% (112/121)95%CI 86.4-96.5%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>277</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>271</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>97.8% (271/277)95%CI 95.3-99.2%</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>N/A</td></tr></table>

One sample was not tested in ELISA

HerpeSelect Express Agreement with ELISA in Capillary Whole Blood with Pregnant Women

The HerpeSelect Express showed $9 6 . 4 \%$ (266/276) agreement with ELISA negatives in samples, and $9 4 . 2 \%$ (114/121), agreement with ELISA positives. Two ELISA equivocals were excluded.

Of the 401 samples, the HerpeSelect 2 ELISA IgG was negative with 276, positive with 121, and equivocal with 3.   
One sample was not tested due to improper storage.

Of the 276 negative HerpeSelect 2 ELISA samples, Express was negative with $9 6 . 4 \%$ (266/276), positive with 9, and invalid with 1.

O  11 positive HerpeSelect 2 ELIA samples, theExpress was negative with7, positive wh $9 4 . 2 \%$ (114/121), and invalid with 0.

# K071510

510(k) Summary of Safety and Effectiveness   
HerpeSelect 1 and 2 Plexus IgG Catalog No. RT0920G Prepared May 31, 2007 Revised September 21, 2007 Page 6 of 13

Express Agreement with ELISA in Capillary Whole Blood with Pregnant Women $( \mathbf { n } = 4 0 1 )$   

<table><tr><td rowspan=2 colspan=1>ELISA</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>HerpeSelect Express</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Invalid</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>121</td><td rowspan=1 colspan=1>114</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>94.2% (114/121)95%CI 88.4-97.6%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>276</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>266</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>96.4% (266/276)95%CI 93.4-98.3%</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>N/A</td></tr></table>

' One sample was not tested in ELISA

# Sensitivity and Specificity with Sexually Active Adults $( \mathbf { n } = \mathbf { 5 } 7 5 )$

External investigator I $( \mathtt { n } = 1 9 5 )$ , External investigator II $( \mathtt { n } = 1 9 0 )$ , and External investigator III $( \mathtt { n } = \mathtt { l 9 0 } )$ assessed t v ulvul bjelo   ubealcT cpilay nveo wholbloodan sfrom sequenl prospeciv subje wee collecestanasked he extelvetatr Themask sampl s bitt he Focus boraory nd teste reference methods.Exteral investigator I was a medical school clinic in Southeaster United States; External ivatr  was  publeah clicate heRocky Mou Regn he UniStaes;anxta invetgator  was udent health clinic heSutheast United States. TheFocus Diagosic HerpeSeec and 2 Immunoblot IgG was the typing reference method for calculation of sensitivity and specificity.

# Sexually Active Adults in Sera

The HerpeSelect Express showed $9 1 . 8 \%$ (315/343) agreement with Immunoblot negatives, and $9 2 . 9 \%$ (210/226) agreement with Immunoblot positives.

Of the 575 sera, the HerpeSelect Immunoblot IG was negative with 343, positive with 226, and equivocal wit 1. Fiv samples were not tested in Immunoblot.Two samples were lost between the Investigator and the Focus Laboratory, and three were not tested due to insufficient quantities.

Of the 343 negative HerpeSelect Immunoblot sera, Express was negative with $9 1 . 8 \%$ (315/343), positive with 28, and invalid with 0.

Of the 226 positive HerpeSelect Immunoblot sera, Express was negative with 14, positive with $9 2 . 9 \%$ (210/226), and invalid with 2.

HerpeSelect Express compared to Immunoblot with Sexually Active Adult in Sera $\mathbf { ( n = 5 7 5 ) }$   

<table><tr><td rowspan=2 colspan=1>Immunoblot</td><td rowspan=2 colspan=1>n&#x27;</td><td rowspan=1 colspan=3>Express</td><td rowspan=2 colspan=1>Specificity</td><td rowspan=2 colspan=1>Sensitivity</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Invalid</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>226</td><td rowspan=1 colspan=1>210</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>92.9% (210/226)95% CI 88.8-95.9%</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>343</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>315</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>91.8% (315/343)95% CI 88.4-94.5%</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>N/A</td></tr></table>

'Five samples were not tested.

# Sexually Active Adults in Venous Whole Blood

The HerpeSelect Express showed $9 2 . 4 \%$ (317/343) agreement with Immunoblot negatives, and $9 3 . 4 \%$ (211/226) agreement with Immunoblot positives.

Of the 575 samples, the HerpeSelect Immunoblot IgG was negative with 343 and positive with 226. Five samples were not tsten Imunoblot.Two samples were ost between he Investigator and theFocus Laboratory, an three were not tested due to insufficient quantities.

Of the 343 negative HerpeSelect Immunoblot samples, Express was negative with $9 2 . 4 \%$ (317/343), positive with 26, and invalid with 0.

Of the 226 positive HerpeSelect Immunoblot samples, Express was negative with 15, positive with $9 3 . 4 \%$ EY (211/226), and invalid with 0.

# K071510

510(k) Summary of Safety and Effectiveness   
HerpeSelect 1 and 2 Plexus IgG Catalog No. RT0920G Prepared May 31, 2007 Revised September 21, 2007 Page 7 of 13

HerpeSelect Express compared to Immunoblot with Sexually Active Adult in Venous Whole Blood $( \mathbf { n } = 5 7 5 )$ EMPY   
Sexually Active Adults in Capillary Whole Blood   

<table><tr><td rowspan=2 colspan=1>Immunoblot</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=3>Express</td><td rowspan=2 colspan=1>Specificity</td><td rowspan=2 colspan=1>Sensitivity</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Invalid</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>226</td><td rowspan=1 colspan=1>211</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>93.4% (211/226)95% CI 89.3-96.2%</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>343</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>317</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>92.4% (317/343)95% CI 89.1-95.0%</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>N/A</td></tr></table>

'Five samples were not tested.

The HerpeSelect Express showed $9 1 . 8 \%$ (315/343) agreement with ELISA negatives, and $9 3 . 8 \%$ (212/226) agreement with Immunoblot positives.

Of the 575 samples, the HerpeSelect Immunoblot $\mathrm { I g G }$ was negative with 343 and positive with 226. Five samples were not teste in Imunoblot.Two samples were ost betweenhe Investigator and the Focus Laboratory, an three were not tested due to insufficient quantities

Of the 343 negative HerpeSelect Immunoblot samples, Express was negative with $9 1 . 8 \%$ (315/343), positive with 28, and invalid with 0.

Of the 226 positive HerpeSelect Immunoblot samples, Express was negative with 14, positive with $9 3 . 8 \%$ (212/226), and invalid with 0.

HerpeSelect Express compared to Immunoblot with Sexually Active Adult in Capillary Whole Blood   
$\mathbf { ( n = 5 7 5 ) }$   

<table><tr><td rowspan=2 colspan=1>Immunoblot</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=3>Express</td><td rowspan=2 colspan=1>Specificity</td><td rowspan=2 colspan=1>Sensitivity</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Invalid</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>226</td><td rowspan=1 colspan=1>212</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>93.8% (212/226)95% CI 89.8-96.6%</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>343</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>315</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>91.8% (315/343)95% CI 88.4-94.5%</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>N/A</td></tr></table>

'Five samples were not tested.

HerpeSelect Express Percent Agreement with HerpeSelect 2 (ELISA) in Sexually Active Adults $( \mathbf { n } = \mathbf { 5 } 7 5 )$ Th old-anaree eo washe Focus Dgosti HepSelc an Ilot Igr clca o ntivity and speciiciy.The device was also evaluated with the HerpeSelect ELISA IgG a cleared preicate device which is not required for regulatory clearance for typing assay.

# HerpeSelect Express Agreement with ELISA in Sera with Sexually Active Adults

The HerpeSelect Express showed $9 8 . 8 \%$ (323/327) agreement with ELISA negatives in sera, and $9 7 . 1 \%$ (236/243) agreement with ELISA positives. Three ELISA equivocals were excluded.

O the 575 sera, the HerpeSelect 2 ELISA IgG was negative with 327, positive with 243, and equivocal with 3. Tw T p  n  .

O te 327 negative HerpeSelect 2 ELISA sera, Express was negative with $9 8 . 8 \%$ (323/327), positive with , d invalid with 0.

O te243 positive HerpeSelect 2 ELISA sera, the Express was negative with 5, positive with $9 7 . 1 \%$ (236/243), and invalid with 2.

Express Agreement with ELISA in Sera with Sexually Active Patients $\mathbf { ( n = 5 7 5 ) }$ EPY   

<table><tr><td rowspan=2 colspan=1>ELISA</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>HerpeSelect Express</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Invalid</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>243</td><td rowspan=1 colspan=1>236</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>97.1% (236/243)95% CI 94.1-98.8%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>327</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>323</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>98.8% (323/327)95% CI 96.9-99.7%</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>N/A</td></tr></table>

Two samples were not tested in ELISA

# K071510

510(k) Summary of Safety and Effectiveness   
HerpeSelect 1 and 2 Plexus IgG Catalog No. RT0920G Prepared May 31, 2007 Revised September 21, 2007 Page 8 of 13

HerpeSelect Express Agreement with ELISA in Venous Whole Blood with Sexually Active Adults

The HerpeSelect Express showed $9 8 . 8 \%$ (322/327) agreement with ELISA negatives in samples, and $9 7 . 1 \%$ (236/243), agreement with ELISA positives. Three ELISA equivocals were excluded.

Of te 575 samples, the HerpeSelect 2 ELISA IgG was negative with 327, positive with 243, and equivocal with 3. To samples were not teste in ELISA.The samples were ost between th Investigatorand the Focus Laboratry. Of the 327 negative HerpeSelect 2 ELISA samples, Express was negative with $9 8 . 8 \%$ (323/327), positive with 4, and invalid with 0.

Of the 243 positive HerpeSelect 2 ELISA samples, the Express was negative with 7, positive with $9 7 . 1 \%$ (236/243), and invalid with O.

Express Agreement with ELISA in Venous Whole Blood with Sexually Active Patients $\mathbf { ( n = 5 7 5 ) }$   

<table><tr><td rowspan=2 colspan=1>ELISA</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>HerpeSelect Express</td><td rowspan=1 colspan=1>EY</td></tr><tr><td rowspan=1 colspan=1>n$</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Invalid</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>243</td><td rowspan=1 colspan=1>236</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>97.1% (236/243)95%CI 94.1-98.8%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>327</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>323</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>98.8% (323/327)95% CI 96.9-99.7%</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>N/A</td></tr></table>

Two samples were not tested in ELISA

# Express in Capillary Whole Blood Agreement with ELISA

The HerpeSelect Express showed $9 8 . 5 \%$ (322/327) agreement with ELISA negatives in samples, and $9 7 . 5 \%$ 237/243) agreement with ELISA positives. Three ELISA equivocals were excluded.

O the 575 samples, the HerpeSelect 2 ELISA IgG was negative with 327, positive with 243, and equivocal with 3. Tosampls were ot este in ELISA.The amples we ost between e Investgator and he Focus Labay. Of the 327 negative HerpeSelect 2 ELISA samples, Express was negative with $9 8 . 5 \%$ (322/327), positive with 5, and invalid with O.

O te 43 posiive HerpeSelect 2 ELIA sampes, the Express was negative with 6, posiiv wth $9 7 . 5 \%$ (237/243), and invalid with 0.

Express Agreement with ELISA in Capillary Whole Blood with Sexually Active Patients $\mathbf { ( n = 5 7 5 ) }$   

<table><tr><td rowspan=2 colspan=1>ELISA</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>HerpeSelect Express</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Invalid</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>243</td><td rowspan=1 colspan=1>237</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>97.5% (237/243)95%CI 94.7-99.1%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>327</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>322</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>98.5% (322/327)95% CI 96.5-99.5%</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>N/A</td></tr></table>

Two samples were not tested in ELISA

# Sensitivity and Specificity with Non-Sexually Active Adults {Low Prevalence} $\bf ( n = 1 0 4 )$

External investigator I $( \boldsymbol { \mathsf { n } } = 4 6 )$ and External investigator $\boldsymbol { \mathrm { I I } }$ EPY $( { \tt n } = 5 8 )$ assessed the device's agreement with nonsexually active adult subjects (low prevalence) from a metropolitan population and student population. The cpilarynv whobloodan fom seqenal proseciv ubje weecolle eanask aheeteal vea eask  mp  uieus boy n ts reference methods.External investigator I was a medical school clinic in Southeaster United States; External investigator I was an TD clinic located in the Paciic Northwest. The Focus Dagnostics HerpeSelect and 2 Immunoblot IgG was the typing reference method for calculation of sensitivity and specificity.

# Non-Sexually Active Adults (Low Prevalence) in Sera

The HerpeSelect Express showed $1 0 0 . 0 \%$ (101/101) agreement with Immunoblot negatives, and $0 . 0 \%$ agreement with Immunoblot positives.

Of the 104 sera, the HerpeSelect Immunoblot IgG was negative with 101 and positive with 2. One sample was not tested in Immunoblot due to insufficient quantities.

Of the 101 negative HerpeSelect Immunoblot sera, Express was negative with $1 0 0 . 0 \%$ (101/101), positive with 0 and invalid with 0.

510(k) Summary of Safety and Effectiveness   
HerpeSelect 1 and 2 Plexus IgG Catalog No. RT0920G Prepared May 31, 2007 Revised September 21, 2007 Page 9 of 13

Of the 2 positive HerpeSelect Immunoblot sera, Express was positive with $0 . 0 \%$ $( 0 / 2 )$ , negative with 2, and invalic with 0.

HerpeSelect Express compared to Immunoblot with Non-Sexually Active Adults (Low Prevalence) in Sera $\{ \pmb { \mathrm { n } } = 1 0 4 \}$   

<table><tr><td rowspan=2 colspan=1>Immunoblot</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=3>Express</td><td rowspan=2 colspan=1>Specificity</td><td rowspan=2 colspan=1>Sensitivity</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Invalid</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0% (0/2)</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>101</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>101</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>100% (101/101)95% CI 96.4-100</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>N/A</td></tr></table>

'One sample was not tested.

# Non-Sexually Active Adults (Low Prevalence) in Venous Whole Blood

The HerpeSelect Express showed $1 0 0 . 0 \%$ (101/101) agreement with Immunoblot negatives, and $0 . 0 \%$ (0/2) agreement with Immunoblot positives.

O te 104 sera, the HerpeSelect Immunoblot IgG was negative with 101 and positive with 2. One sample was not ested in Immunoblot due to insufficient quantities.

Of the 101 negative HerpeSelect Immunoblot sera, Express was negative with $1 0 0 . 0 \%$ (101/101), positive with 0, and invalid with 0.

Of the 2 positive HerpeSelect Immunoblot sera, Express was positive with $0 . 0 \%$ EY $( 0 / 2 )$ , negaive with , and inval with 0.

HerpeSelect Express compared to Immunoblot with Non-Sexually Active Adults (Low Prevalence) in Venous Whole Blood $\mathbf { ( n = 1 0 4 ) }$   

<table><tr><td rowspan=2 colspan=1>Immunoblot</td><td rowspan=2 colspan=1>n&#x27;</td><td rowspan=1 colspan=3>Express</td><td rowspan=2 colspan=1>Specificity</td><td rowspan=2 colspan=1>Sensitivity</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Invalid</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0% (0/2)</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>101</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>101</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>100% (101/101)95% CI 96.4-100</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>N/A</td></tr></table>

'One sample was not tested.

# on-Sexually Active Adults (Low Prevalence) in Capillary Whole Blood

The HerpeSelect Express showed $1 0 0 . 0 \%$ (101/101) agreement with Immunoblot negatives, and $0 . 0 \%$ (0/2) agreement with Immunoblot positives.   
Othe 104 sera, the HerpeSelect Immunoblot IgG was negative with 101 and positive with . One sample was not tested in Immunoblot due to insufficient quantities.   
Of the 101 negative HerpeSelect Immunoblot sera, Express was negative with $1 0 0 . 0 \%$ (101/101), positive with 0, and invalid with 0.   
Of the 2 positive HerpeSelect Immunoblot sera, Express was positive with $0 . 0 \%$ EY $( 0 / 2 )$ , negative with 2, and invalid with 0.

HerpeSelect Express compared to Immunoblot with Non-Sexually Active Adults (Low Prevalence) in Capillary Whole Blood   

<table><tr><td rowspan=2 colspan=1>Immunoblot</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=3></td><td rowspan=2 colspan=1>Specificity</td><td rowspan=2 colspan=1>Sensitivity</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Invalid</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0% (0/2)</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>101</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>101</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>100% (101/101)95% CI 96.4-100</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>N/A</td></tr></table>

'One sample was not tested.

# HerpeSelect Express Percent Agreement with Focus Diagnostics HerpeSelect 2 (ELISA) with Non-Sexually Active Adults {Low Prevalence} $\bf ( n = 1 0 4 )$

The gold-standard reference method was the Focus Diagnostics HerpeSelect  and 2 Immunoblot IgGfor calculation oiiviy and specificity.The device was also evaluated with the HerpeSelect ELISA IG a leare preicate device which is not required for regulatory clearance for typing assay.

HerpeSelect Express in Sera Agreement with ELISA

The HerpeSelect Express showed $1 0 0 . 0 \%$ (102/102) agreement with ELISA negatives in sera, and, $0 . 0 \%$ EMPY $( 0 / 1 )$ agreement with ELISA positives. One ELISA equivocal was excluded.

Of the 104 sera, the HerpeSelect 2 ELISA IgG was negative with 102, positive with 1, and equivocal with 1.

Of the 102 negative HerpeSelect 2 ELISA sera, the Express was negative with $1 0 0 . 0 \%$ (102/102), positive with 0, and invalid with O.

Of the 1 positive HerpeSelect 2 ELISA sera, Express was negative with 1, positive with $0 . 0 \%$ $( 0 / 1 )$ , and invalid with 0.

Express Agreement with ELISA in Sera with Non-Sexually Active Adults{Low Prevalence} $( \mathbf { n } = \mathbf { 1 0 4 } )$ EY   

<table><tr><td rowspan=2 colspan=1>ELISA</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>HerpeSelect Express</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Invalid</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0% (0/1)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>102</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>102</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100% (102/102)95% CI 96.4-100%</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>N/A</td></tr></table>

lerpeSelect Express in Venous Whole Blood Agreement with ELISA

The HerpeSelect Express showed $1 0 0 . 0 \%$ (102/102) agreement with ELISA negatives in sera, and, $0 . 0 \%$ (0/1 agreement with ELISA positives. One ELISA equivocal was excluded.

Of the 104 sera, the HerpeSelect 2 ELISA IgG was negative with 102, positive with 1, and equivocal with 1.

O te 102 negative HerpeSelect 2 ELISA sera, the Express was negative with $1 0 0 . 0 \%$ (102/102), positive with 0, ind invalid with 0.

O   posiive HerpeSelect  ELISA sra Express was neative with 1, posive with $0 . 0 \%$ EY $( 0 / 1 )$ , and invalid with D.

Express Agreement with ELISA in Venous Whole Blood with Non-Sexually Active Adults {Low Prevalence} $( \mathbf { n } = \mathbf { 1 0 4 } )$   

<table><tr><td rowspan=2 colspan=1>ELISA</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=3>HerpeSelect Express</td><td rowspan=2 colspan=1>% Agreement</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Invalid</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0% (0/1)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>102</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>102</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100% (102/102)95% CI 96.4-100</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>N/A</td></tr></table>

Express in Capillary Whole Blood Agreement with ELISA

The HerpeSelect Express showed $1 0 0 . 0 \%$ (102/102) agreement with ELISA negatives in sera, and, $0 . 0 \%$ (0/1) agreement with ELISA positives. One ELISA equivocal was excluded.

f the 104 sera, the HerpeSelect 2 ELISA IgG was negative with 102, positive with 1, and equivocal with 1.

O the 102 negative HerpeSelect 2 ELISA sera, the Express was negative with $1 0 0 . 0 \%$ (102/102), positive with 0, and invalid with O.

Of te  posiive HerpeSelect  ELISA sera, Express was negative with 1, postive wih $0 . 0 \%$ $( 0 / 1 )$ , and invalid with 0.

510(k) Summary of Safety and Effectiveness   
HerpeSelect 1 and 2 Plexus IgG Catalog No. RT0920G Prepared May 31, 2007 Revised September 21, 2007 Page 11 of 13

Express Agreement with ELISA in Capillary Whole Blood with Non-Sexually Active Adults {Low Prevalence}   
${ \bf ( n = 1 0 4 ) }$   

<table><tr><td rowspan=2 colspan=1>ELISA</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=3>HerpeSelect Express</td><td rowspan=2 colspan=1>% Agreement</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Invalid</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0% (0/1)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>102</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>102</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100% (102/102)95% CI 96.4-100%</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>N/A</td></tr></table>

# Agreement with CDC Panel $\mathbf { ( n = 1 0 0 ) }$

The following information is from a serum panel obtained from the CDC and tested by Focus Diagnostics.Results fromhe panel wee reviousy eceive durig udies r e lexus HerpeSelect Mulnaly Dagosti Thee results ere masked om he person perorming the testig wh theExpres device nd the persn performi the a with a masked, characterized serum panel and do not imply an endorsement of the assay by the CDC.

The t pnel const  100 smplesThee r 65 HSV native and 35 HSV- psitive ses.

Determination of positive and negative samples Ot 65 HSV-2 negative samples, the HerpeSelect Express IgGcorrectly identified $9 8 . 5 \%$ (64/65). Of the 35 HSV-2 positive samples, the HerpeSelect® Express IgG correctly identified $100 \%$ (35/35).

Agreement with CDC Panel $\mathbf { ( n = 1 0 0 ) }$ EP   

<table><tr><td rowspan=2 colspan=1>CDC HSV2</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=3>HerpeSelect®IExpress</td><td rowspan=2 colspan=1>% Agreement</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Invalid</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100% (35/35) 95% CI 90.0-100.0%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>65</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>64</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>98.5% (64/65) 95% CI 91.7 -100.0%</td></tr></table>

# Cross-Reactivity $( \mathbf { n } = 2 \mathbf { 1 } 3 )$

• $( \mathbf { n } \mathbf { = } 2 5 )$ Herpes Simplex 1 Virus (HSV-1) • $( \mathtt { n } \mathtt { = } 2 5 )$ Rubella virus • EP $( \boldsymbol { \mathrm { n } } \boldsymbol { = } 4 2 )$ Varicella-Zoster virus, (VZV) . $( \mathtt { n } = 2 5 )$ Epstein-Barr virus (EBV) o $( \mathtt { n } \mathtt { = } 3 2 )$ Cytomegalovirus (CMV) • EY $\mathrm { ( n } \mathrm { = } 3 3 )$ Rheumatoid Factor (RF) EPY $\scriptstyle ( \mathtt { n } = 3 1 )$ Anti-nuclear Antibodies (ANA)

# Express Reactivity with Cross-Reactants

The HerpeSelect Express showed $4 . 2 \%$ (9/213)overall cross-reactiviy.

With the HSV-1 IgG positives the Express was positive with $0 . 0 \%$ (0/25), negative with 25, and invalid with 0.   
With the Rubella virus positives the Express was positive with $4 . 0 \%$ (1/25), negative with 24, and invalid with 0.   
With the VZV IgG positives the Express was positive with $9 . 5 \%$ negative with 38 and invalid w.   
With the EBV IgG positives the Express was positive with $4 . 0 \%$ (1/25), negative with 24, and invalid with 0.   
With the CMV IgG positives the Express was positive with $3 . 1 \%$ (1/2, negative with 31, and invalid with 0.   
With the RF posies te Exprss was psiv h $3 . 0 \%$ (1/), negative with 3, and invalid wih 0.   
With the ANA positives the Express was positive with $3 . 2 \%$ (/1, negative with 30, and invalid with 0.   
510(k) Summary of Safety and Effectiveness   
HerpeSelect 1 and 2 Plexus IgG Catalog No. RT0920G Prepared May 31, 2007 Revised September 21, 2007 Page 12 of 13

Express Agreement Cross-Reactant   

<table><tr><td rowspan=2 colspan=1>Cross-reactant</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=3>HerpeSelect Express</td><td rowspan=2 colspan=1>% Cross-Reactivity</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Invalid</td></tr><tr><td rowspan=1 colspan=1>HSV-1 IgG +</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0% (0/25)95%CI 0.0 - 13.7%</td></tr><tr><td rowspan=1 colspan=1>Rubella +</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4.0% (1/25)95%CI 0.0 - 20.4%</td></tr><tr><td rowspan=1 colspan=1>VZV IgG +</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>38</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>9.5% (4/42)95%CI 2.7 - 22.6%</td></tr><tr><td rowspan=1 colspan=1>EBV IgG +</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4.0% (1/25)95%CI 0.0 - 20.4%</td></tr><tr><td rowspan=1 colspan=1>CMV IgG +</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3.1% (1/32)95%CI 0.0-16.2%</td></tr><tr><td rowspan=1 colspan=1>RF +</td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3.0% (1/33)95%CI 0.0 - 15.8%</td></tr><tr><td rowspan=1 colspan=1>ANA +</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3.2% (1/31)95%CI 0.0-15.8%</td></tr><tr><td rowspan=1 colspan=1>Combined Cross-reactants</td><td rowspan=1 colspan=1>213</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>204</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4.2% (9/213)95%CI 1.9.0-7.8%</td></tr></table>

# Interference

T  e  valua  esje we pos hee mp vis-neativ rpe spe n egativoh hepe pex vi herpes simplex virus 2 by HerpeSelect ELISA IgG. Baseline levels for triglycerides, albumin, bilirubin, and hgob ablish sbjTe in was i purhasteerent whic exceeded the expected human range. The spiked samples were tested againn the assay to determine  the e yoat the positive or negative sample.

# Matrix Comparison

Focus compared the device's relative reactivity with serum with venous whole blood by spiking a HerpeSelect 2 ELISAps avi whblh loan tesg hedilu s and blo wi e vic atsT tre e replicates end-pointed at 1:8 and one at 1:4. Three of three whole blood replicates end-pointed at 1:4.

# Reproducibility

Fcs, a cinial boratoylocate inSouthe Califonia, a publichealth cic located in theRocky Mount Rhni ta eal cSuUn tat nc the PacicNorthwest assesedthedevice'sInter-lot,Inter/Inta-operator reproducibiliy and Inter/Intra-si reproducibility. Each of the sites tested at ten samples in singlicate on three different days.

<table><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=3>Inter-Lot Reproducibility</td><td rowspan=1 colspan=3>Inter-Operator</td><td rowspan=1 colspan=2>Inter-Site</td></tr><tr><td rowspan=1 colspan=1>ELISARange</td><td rowspan=1 colspan=1>SampleID</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>Accuracy</td><td rowspan=1 colspan=1>Precision</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>Accuracy</td><td rowspan=1 colspan=1>Precision</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>High Negative</td><td rowspan=1 colspan=1>HSV-1</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1>Borderline</td><td rowspan=1 colspan=1>HSV-2</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>98.8%</td><td rowspan=1 colspan=1>96.3%</td><td rowspan=1 colspan=1>3.7%</td><td rowspan=1 colspan=1>98.8%</td><td rowspan=1 colspan=1>97.8%</td><td rowspan=1 colspan=1>2.2%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>HSV-11</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>97.5%</td><td rowspan=1 colspan=1>92.4%</td><td rowspan=1 colspan=1>7.6%</td><td rowspan=1 colspan=1>97.5%</td><td rowspan=1 colspan=1>95.6%</td><td rowspan=1 colspan=1>4.4%</td></tr><tr><td rowspan=1 colspan=1>High Positive</td><td rowspan=1 colspan=1>HSV-12</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>HSV-13</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>97.5%</td><td rowspan=1 colspan=1>92.4%</td><td rowspan=1 colspan=1>7.6%</td><td rowspan=1 colspan=1>97.5%</td><td rowspan=1 colspan=1>95.6%</td><td rowspan=1 colspan=1>4.4%</td></tr><tr><td rowspan=1 colspan=1>Low Positive</td><td rowspan=1 colspan=1>HSV-14</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>59.3%</td><td rowspan=1 colspan=1>35.0%</td><td rowspan=1 colspan=1>65.0%</td><td rowspan=1 colspan=1>59.3%</td><td rowspan=1 colspan=1>65.2%</td><td rowspan=1 colspan=1>34.8%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>HSV-15</td><td rowspan=1 colspan=1>77.8%</td><td rowspan=1 colspan=1>24.7%</td><td rowspan=1 colspan=1>82.7%</td><td rowspan=1 colspan=1>71.4%</td><td rowspan=1 colspan=1>28.6%</td><td rowspan=1 colspan=1>82.7%</td><td rowspan=1 colspan=1>83.0%</td><td rowspan=1 colspan=1>17.0%</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>HSV-26</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>97.5%</td><td rowspan=1 colspan=1>95.0%</td><td rowspan=1 colspan=1>5.0%</td><td rowspan=1 colspan=1>97.5%</td><td rowspan=1 colspan=1>97.8%</td><td rowspan=1 colspan=1>2.2%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>HSV-27</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>HSV-28</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>98.8%</td><td rowspan=1 colspan=1>96.3%</td><td rowspan=1 colspan=1>3.7%</td><td rowspan=1 colspan=1>98.8%</td><td rowspan=1 colspan=1>97.8%</td><td rowspan=1 colspan=1>2.2%</td></tr></table>

<table><tr><td rowspan=1 colspan=4>Intra-Operator</td></tr><tr><td rowspan=1 colspan=1>Operator</td><td rowspan=1 colspan=1>Accuracy</td><td rowspan=1 colspan=1>Precision</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>96.7%</td><td rowspan=1 colspan=1>89.1%</td><td rowspan=1 colspan=1>10.9%</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>97.8%</td><td rowspan=1 colspan=1>95.2%</td><td rowspan=1 colspan=1>4.8%</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>90.0%</td><td rowspan=1 colspan=1>64.9%</td><td rowspan=1 colspan=1>35.1%</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>98.9%</td><td rowspan=1 colspan=1>96.4%</td><td rowspan=1 colspan=1>3.6%</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>87.8%</td><td rowspan=1 colspan=1>70.5%</td><td rowspan=1 colspan=1>29.5%</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>96.7%</td><td rowspan=1 colspan=1>89.1%</td><td rowspan=1 colspan=1>10.9%</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>87.8%</td><td rowspan=1 colspan=1>86.1%</td><td rowspan=1 colspan=1>13.9%</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>92.2%</td><td rowspan=1 colspan=1>77.2%</td><td rowspan=1 colspan=1>22.8%</td></tr><tr><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>91.1%</td><td rowspan=1 colspan=1>69.1%</td><td rowspan=1 colspan=1>30.9%</td></tr><tr><td rowspan=1 colspan=3>Intra-Site</td><td rowspan=1 colspan=1>canmaGentalow</td></tr><tr><td rowspan=1 colspan=1>Site</td><td rowspan=1 colspan=1>Accuracy</td><td rowspan=1 colspan=1>Precision</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>94.8%</td><td rowspan=1 colspan=1>87.6%</td><td rowspan=1 colspan=1>12.4%</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>94.4%</td><td rowspan=1 colspan=1>87.3%</td><td rowspan=1 colspan=1>12.7%</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>90.4%</td><td rowspan=1 colspan=1>79.0%</td><td rowspan=1 colspan=1>21.0%</td></tr></table>

Ms. Constance Bridges   
Director, Regulatory and Compliance Focus Diagnostics, Inc.   
10703 Progress Way   
Cypress, CA 90630

SEP 2 4 2007

Re: k071510 Trade/Device Name: HerpeSelect® Express IgG Regulation Number: 21 CFR 866.3305 Regulation Name: Herpes simplex virus serological reagents Regulatory Class: Class II Product Code: MYF Dated: May 31, 2007 Received: June 4, 2007

Dear Ms. Bridges:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class II (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 -

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at 240-276-0450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index,html.

Sincerely yours,

Sall attoy

Sally A. Hojvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and   
Radiological Health

Enclosure

# 510(k) Number (if known): K071510

Device Name:

HerpeSelect Express IgG

Indications for Use:

HerpeSelect® Express is a rapid test intended for qualitatively detecting the presence or absence of human IgG class antibodies to herpes simplex virus type 2 (HSV-2) in human whole blood (venous or capillary) or serum. The test is indicated for testing sexually active adults or pregnant women to aid in the presumptive diagnosis of HSV-2 infection.

The HerpeSelect $\textsuperscript { \textregistered }$ Express IgG device has not been established for use in the pediatrics population, for neonatal screening, or for testing immunocompromised patients. This kit is not intended for self-testing, and this test is neither FDA cleared nor approved for testing blood or plasma donors.

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

![](images/069ceb6f7fd881b437ba9ea12b94c4a8fa70da437317c794431e11ee858b0f39.jpg)  
Page 1 of 1

Office of In Vitro Diagnostic Device Evaluation and Safety